Vicus Therapeutics is a private biopharmaceutical company dedicated to bringing breakthrough multi-drug treatments to patients with cancer. Vicus focuses on identifying drugs that have already gained FDA approval for non-cancer indications and have completed initial clinical testing for the treatment of cancer-related indications.

Vicus partners with pharmaceutical companies and then develops these drugs as components of multi-drug treatment regimens that can enhance the effectiveness of the partners’ FDA-approved targeted oncology drug products. Because all the components of the multi-drug regimens are already FDA-approved, patients can gain access to the new treatments as soon as positive clinical results are published.

Vicus’ lead product, VT-122, is designed to enhance the effectiveness of targeted drug therapies for advanced cancer patients with systemic inflammation. Systemic inflammation in advanced cancer manifests as cachexia and is associated with intolerance to therapy, poor quality-of-life and reduced life expectancy. In a Phase 2 study of advanced lung cancer patients, VT-122 demonstrated a statistically significant improvement in lean body mass, an endpoint reflective of systemic inflammation.